Sidharth Kerkar
Founder & Chief Executive Officer AllerGene AI Therapeutics
Sid is a pharma and biotech leader and cell therapy innovator whose work helped establish MAGE-A as a pan-cancer immunotherapy target and advanced next-generation IL-12–engineered T cell therapies. He is now pioneering in vivo gene engineering approaches to treat and potentially prevent life-threatening allergies, anaphylaxis, mast cell–driven diseases, and select leukemias.
Seminars
Thursday 30th July 2026
In Vivo mRNA-LNP CAR-T Cells Targeting Mast Cells for Mast Cell-Driven Diseases, Severe Allergies & Anaphylaxis
11:00 am
- Defining the unmet medical need that can be fulfilled with an in vivo CAR-T approach
- Ideal features necessary for a safe and effective mast cell target
- Design and function of novel mRNA-LNP CAR constructs targeting human mast cells
